Identification of miRNAs as prognostic factors for esophageal squamous cell carcinoma

Meng Chen; Dacheng Jin; Bing Wang; Yunjiu Gou; Xinchun Dong; Meng Chen; Dacheng Jin; Bing Wang; Yunjiu Gou; Xinchun Dong

doi:10.3934/mbe.2020122

Mathematical Biosciences and Engineering

2020, Volume 17, Issue 3: 2302-2309. doi: 10.3934/mbe.2020122

Previous Article Next Article

Research article Special Issues

Identification of miRNAs as prognostic factors for esophageal squamous cell carcinoma

1.
Gansu University of Chinese Medicine, Lanzhou 730000, China
2.
Department of Thoracic Surgery, Gansu Provincial Hospital, No. 204 Donggang West Road, Lanzhou 730000, China

Received: 31 May 2019 Accepted: 20 November 2019 Published: 17 January 2020

ObjectiveThe prognostic value of microRNAs for esophageal squamous cell carcinoma (ESCC) is still not be well identified.

MethodsThe microRNA expression profiles of 119 paired ESCC tissue samples and para-carcinoma tissues from GEO database under accession number of GSE43732. A mutation information based feature selection method was applied to identify the discriminative microRNAs between paired ESCC tissues and para-carcinoma tissues.

ResultsIn para-carcinoma tissues, patients had better survival with higher has-miR-410 (log-rank p = 0.0123), has-miR-411-5p (log-rank p = 0.0152), has-miR-193b-5p (log-rank p = 0.0188) and has-miR-4486 (log-rank p = 0.0307) expression levels. When compared with para-carcinoma tissues, there has more correlations between miRNA expression levels and survival in tumor tissues. We identified 20 potential miRNAs associated with prognosis. Besides, a heatmap was draw to explore miRNA expression levels in tumor tissues and survival.

ConclusionsThe present study identified 24 miRNAs in 119 paired ESCC tissue samples and para-carcinoma tissues, including 4 miRNAs in para-carcinoma tissues and 20 in tumor tissues, respectively. The dysregulation of these miRNAs were associated with different outcomes. We thought this study could provide novel noninvasive early biomarkers for ESCC patients.
- esophageal squamous cell carcinoma,
- microRNAs,
- prognosis,
- genes,
- tumor
Citation: Meng Chen, Dacheng Jin, Bing Wang, Yunjiu Gou, Xinchun Dong. Identification of miRNAs as prognostic factors for esophageal squamous cell carcinoma[J]. Mathematical Biosciences and Engineering, 2020, 17(3): 2302-2309. doi: 10.3934/mbe.2020122

Related Papers:

Abstract

ObjectiveThe prognostic value of microRNAs for esophageal squamous cell carcinoma (ESCC) is still not be well identified.

MethodsThe microRNA expression profiles of 119 paired ESCC tissue samples and para-carcinoma tissues from GEO database under accession number of GSE43732. A mutation information based feature selection method was applied to identify the discriminative microRNAs between paired ESCC tissues and para-carcinoma tissues.

ResultsIn para-carcinoma tissues, patients had better survival with higher has-miR-410 (log-rank p = 0.0123), has-miR-411-5p (log-rank p = 0.0152), has-miR-193b-5p (log-rank p = 0.0188) and has-miR-4486 (log-rank p = 0.0307) expression levels. When compared with para-carcinoma tissues, there has more correlations between miRNA expression levels and survival in tumor tissues. We identified 20 potential miRNAs associated with prognosis. Besides, a heatmap was draw to explore miRNA expression levels in tumor tissues and survival.

ConclusionsThe present study identified 24 miRNAs in 119 paired ESCC tissue samples and para-carcinoma tissues, including 4 miRNAs in para-carcinoma tissues and 20 in tumor tissues, respectively. The dysregulation of these miRNAs were associated with different outcomes. We thought this study could provide novel noninvasive early biomarkers for ESCC patients.

References

[1]	W. Chen, R. Zheng, P. D. Baade, S. Zhang, H. Zeng, F. Bray, et al., Cancer statistics in China, 2015, Ca-Cancer J. Clin., 66 (2016), 115-132.
[2]	Z. Chen, J. Li, L. Tian, C. Zhou, Y. Gao, F. Zhou, et al., MiRNA expression profile reveals a prognostic signature for esophageal squamous cell carcinoma, Cancer Lett., 350 (2014), 34-42.
[3]	H. Z. Zhang, G. F. Jin, H. B. Shen, Epidemiologic differences in esophageal cancer between Asian and Western populations, Chin. J. Cancer, 2012, 31 (2012), 281.
[4]	Y. Guo, Z. Chen, L. Zhang, F. Zhou, S. Shi, X Feng, et al., Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma, Cancer Res., 68 (2008), 26-33.
[5]	X. Wang, D. Kong, C. Wang, X. Ding, L. Zhang, M. Zhao, et al., Circulating microRNAs as novel potential diagnostic biomarkers for ovarian cancer: a systematic review and updated meta-analysis, J Ovarian Res., 12 (2019), 24.
[6]	C. W. Kan, V. M. Howell, M. A. Hahn, D. J. Marsh, Genomic alterations as mediators of miRNA dysregulation in ovarian cancer, Genes. Chromosomes Cancer, 54 (2015), 1-19.
[7]	X. H. Hu, J. Dai, H. L. Shang, Z. X. Zhao, Y. D. Hao, MiR-1285-3p is a potential prognostic marker in human osteosarcoma and functions as a tumor suppressor by targeting YAP1, Cancer Biomarkers, 25 (2019), 1-10.
[8]	J. von Frowein, S. M. Hauck, R. Kappler, P. Pagel, K. K. Fleischmann, T. Magg, et al., MiR‐492 regulates metastatic properties of hepatoblastoma via CD 44, Liver Int., 38 (2018), 1280-1291.
[9]	A. Fesler, H. Zhai, J. Ju, MiR-129 as a novel therapeutic target and biomarker in gastrointestinal cancer, OncoTargets Ther., 7 (2014), 1481.
[10]	A. Szpechcinski, M. Florczuk, K. Duk, A. Zdral, S. Rudzinski, M. Bryl, et al., The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients, Cell. Mol. Life Sci., 2019, 1-16.
[11]	Y. Tan, J. J. Lin, X. Yang, D. M. Gou, L. Fu, F. R Li, et al., A panel of three plasma microRNAs for colorectal cancer diagnosis, Cancer Epidemiol., 60 (2019), 67-76.
[12]	L. L. Wong, R. Zou, L. Zhou, J. Y. Lim, D. C. Phua, C. Liu, et al., Combining Circulating MicroRNA and NT-proBNP to Detect and Categorize Heart Failure Subtypes, J. Am. Coll. Cardiol., 73 (2019), 1300-1313.
[13]	N. S. Altman, An introduction to kernel and nearest-neighbor nonparametric regression, Am. Stat., 46 (1992), 175-185.
[14]	T. H. Zhao, M. Jiang, T. Huang, B. Q. Li, N. Zhang, H. P. Li, et al, A novel method of predicting protein disordered regions based on sequence features, Biomed. Res. Int., 2013 (2013).
[15]	A. K. Rustgi, H. B. El-Serag, Esophageal carcinoma, New Engl. J Med., 371 (2014), 2499-2509.
[16]	Y. Song, L. Li, Y. Ou, Z. Gao, E. Li, X. Li, et al., Identification of genomic alterations in oesophageal squamous cell cancer, Nature, 509 (2014), 91.
[17]	K. J. Kaneko, M. L. DePamphilis, Regulation of gene expression at the beginning of mammalian development and the TEAD family of transcription factors, Dev. Genet., 22 (1998), 43-55.
[18]	Z. Shi, F. He, M. Chen, L. Hua, W. Wang, S. Jiao, et al., DNA-binding mechanism of the Hippo pathway transcription factor TEAD4, Oncogene, 36 (2017), 4362.
[19]	N. Nishioka, S. Yamamoto, H. Kiyonari, H. Sato, A. Sawada, M. Ota, et al., Tead4 is required for specification of trophectoderm in pre-implantation mouse embryos, Mech. Develop., 125 (2008), 270-283.
[20]	N. Nishioka, K. I. Inoue, K. Adachi, H. Kiyonari, M. Ota, A. Ralston, et al., The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass, Dev. Cell, 16 (2009), 398-410.
[21]	S. Takeuchi, A. Kasamatsu, M. Yamatoji, D. Nakashima, Y. Endo-Sakamoto, N. Koide, et al., TEAD4-YAP interaction regulates tumoral growth by controlling cell-cycle arrest at the G1 phase, Biochem. Biophys. Res. Commun., 486 (2017), 385-390. doi: 10.1016/j.bbrc.2017.03.050
[22]	Y. Liu, G. Wang, Y. Yang, Z. Mei, Z. Liang, A. Cui, et al., Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner, Oncogene, 35 (2016), 2789.
[23]	Q. Zhang, H. Fan, Q. Zou, H. Liu, B. Wan, S. Zhu, et al., TEAD 4 exerts pro‐metastatic effects and is negatively regulated by miR6839‐3p in lung adenocarcinoma progression, J Cell. Mol. Med., 22 (2018), 3560-3571.
[24]	S. M. Wang, W. X. Zeng, W. S. Wu, L. L. Sun, D. Yan,. Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia, Leukemia Res., 65 (2018), 61-66.
[25]	R. Fang, Y. Zhu, L. Hu, J. Ai, H. Zou, D. Ju, et al., Plasma MicroRNA Pair Panels as Novel Biomarkers for Detection of Early Stage Breast Cancer, Front. Physiol., 9, (2018),1879.
[26]	M. A.Chaudhry, Radiation‐induced microRNA: Discovery, functional analysis, and cancer radiotherapy, J Cell. Biochem., 115 (2014), 436-449.
[27]	E. van Schooneveld, H. Wildiers, I. Vergote, P. B. Vermeulen, L. Y. Dirix, et al., Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management, Breast Cancer Res., 17 (2015), 21.
[28]	J. Li, X. Kong, J. Zhang, Q. Luo, X. Li, L. Fang, MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer, Cancer Cell Int., 13 (2013), 7.
[29]	C. M. Wilke, J. Hess, S. V. Klymenko, V. V. Chumak, L. M. Zakhartseva, E. V. Bakhanova, et al., Expression of mi RNA‐26b‐5p and its target TRPS 1 is associated with radiation exposure in post‐C hernobyl breast cancer, Int. J Cancer, 142 (2018), 573-583.
[30]	T. Liu, X. You, J. Sui, B. Shen, Y. Zhang, X. M. Zhang, et al., Prognostic value of a two‐microRNA signature for papillary thyroid cancer and a bioinformatic analysis of their possible functions, J Cell. Biochem., 120 (2019), 7185-7198.
[31]	M. L. Slattery, J. S. Herrick, L. E. Mullany, N. Valeri, J. Stevens, B. J. Caan, et al., An evaluation and replication of mi RNA s with disease stage and colorectal cancer‐specific mortality, Int. J Cancer, 137 (2015), 428-438.
[32]	L. Falzone, L. Scola, A. Zanghì, A. Biondi, A. D. Cataldo, M. Libra, et al., Integrated analysis of colorectal cancer microRNA datasets: Identification of microRNAs associated with tumor development, Aging, 10 (2018), 1000.
[33]	L. Falzone, L. Scola, A. Zanghì, A. Biondi, A. Di Cataldo, M. Libra, et al., MicroRNA-125b-5p regulates IL-1β induced inflammatory genes via targeting TRAF6-mediated MAPKs and NF-κB signaling in human osteoarthritic chondrocytes, Sci. Rep., 9 (2019), 6882.
[34]	A. Zeybek, N. Öz, S. Kalemci, T. Edgünlü, M. T. Kızıltuğ, K. Tosun, et al., Diagnostic Value of MiR-125b as a Potential Biomarker for Stage I Lung Adenocarcinoma Lung Adenocarcinoma, Curr. Mol. Med., 19 (2019), 216-227.
[35]	C. Martínez, B. K. Rodiño-Janeiro, B. Lobo, M. L. Stanifer, B. Klaus, M. Granzow, et al., MiR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhea, Gut, 66 (2017), 1537-1538.
[36]	X. Yang, C. Zhang, H. Tie, J. Luo, Y. Wang, Q. Wu, MiR-760 exerts an antioncogenic effect in esophageal squamous cell carcinoma by negatively driving fat metabolism via targeting c-Myc, J Cell. Biochem., 2019.
[37]	J. Tang, Z. Li, Q. Zhu, W. Wen, J. Wang, J. Xu, et al., MiR‐204‐5p regulates cell proliferation, invasion, and apoptosis by targeting IL‐11 in esophageal squamous cell carcinoma, J Cell. Physiol., 2019.

Reader Comments

Your name:*

Email:*
© 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)